ClinicalTrials.gg
Enrolling by invitationNCT07619729Updated Sep 3, 2026

Evaluate the Efficacy of an Oral Health Behavioral Intervention in People With Diabetes

A Phase 4 interventional study of Diabetes Oral Health Program and Stannous Fluoride Dentifrice in Diabetes Type 2, Periodontal Disease and Caries, sponsored by Colgate Palmolive. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-03.

Sponsored by Colgate Palmolive · Phase 4, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
10,000
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 3,304 studies in Diabetes Mellitus, Type 2 with a site in United States — 343 open to participants now, 478 under way, 51 of them phase 3. Diabetes Mellitus, Type 2 · United States.

Planned enrollment
23rd of 2,957
10,000 · median 90
Started
2026
with 152 others
Phase 4
300 of 3,304
19 open now
Primary completion
2028-01
later than 351 of 476 live
Registered
3,245th of 3,304
by date

Among the 3,304 studies in Diabetes Mellitus, Type 2 with a site in United States, this one is the 23rd largest by planned enrollment of the 2,957 interventional ones that give a count, is one of 153 that started in 2026, is one of 300 in phase 4, reaches primary completion later than 351 of the 476 other live ones, and was the 3,245th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

343 of the 3,304 studies in Diabetes Mellitus, Type 2 with a site in United States are open now. Recruiting first, the newest first:

338 more — sign in →

All 343 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,304 studies in Diabetes Mellitus, Type 2 with a site in United States, or all of them as a file.
02

Study summary

The purpose of this clinical study is to evaluate the effect of a behavioral intervention on the number of preventive and treatment dental claims in a population of people with Type 2 Diabetes.

03

Conditions studied

  • Diabetes Type 2
  • Periodontal Disease
  • Caries

Keywords

  • type 2 diabetes
  • oral health
  • periodontal disease
  • caries
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Consented to participation in the Fidelis Care Diabetes Care program.
  • Aged 18 years and older
  • English speaking.
  • Willing and able to receive text messages, and participate in online activities for the duration of the program.
  • Diagnosis of Type 2 Diabetes.

Exclusion criteria

Exclusion Criteria:

  • Severe cognitive impairment.
  • General anesthesia in the past 3 months.
  • Type 1 diabetes.
  • Self-reported pregnant.
05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10,000 participants (estimated)

Study arms

  • Experimental
    Type 2 Diabetes

    This is a single-group study. All subjects will be enrolled in the experimental group.

    Behavioral: Diabetes Oral Health Program · Drug: Stannous Fluoride Dentifrice · Drug: Cetylpyridinium Chloride (CPC) and Zinc Lactate Mouthwash

Interventions

  • BehavioralDiabetes Oral Health Program

    All subjects will receive a behavioral intervention through text messages with links to educational pages about oral health or diabetes. Subjects will have the option of selecting in to the product intervention.

  • This is an opt-in product intervention, and it is expected that not all subjects will opt-in. Subjects will need to re-order the product every 3 months. All subjects who order product will receive a toothbrush, toothpaste, and mouthwash.

  • DrugCetylpyridinium Chloride (CPC) and Zinc Lactate Mouthwash

    Drug pages: Cetylpyridinium · Zinc lactate

    This is an opt-in product intervention, and it is expected that not all subjects will opt-in. Subjects will need to re-order the product every 3 months. All subjects who order product will receive a toothbrush, toothpaste, and mouthwash.

    Also known as: CPC + Zn, CPC + Zinc, mouthwash

06

What researchers measure

Primary outcomes

  1. Dental Claims

    Percentage of preventive dental claims compared to treatment dental claims

    Time frame: 12 months

Secondary outcomes

  1. Product usage

    Number of subjects who opt-in to the product intervention

    Time frame: 12 months

07

Study locations

1 site
  • Decentralized Site - Virtual/Remote (NY, USA)
    Long Island City, New York 11101, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Jan 2028, 19 months after the start.

Of 132 industry-sponsored phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 28. This study's planned 19 months is close to that.

Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2026
First posted
Jun 2, 2026
StartActual
May 26, 2026
Primary completionEst.
Jan 2, 2028
CompletionEst.
Jan 2, 2028
Last update
Sep 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07619729
Lead sponsor
Colgate Palmolive
Responsible party
Sponsor
First posted
Jun 2, 2026
Start date
May 26, 2026
Primary completion
Jan 2, 2028 (estimated)
Completion
Jan 2, 2028 (estimated)
Last update
Sep 3, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tin Fluorides · Cetylpyridinium · Zinc lactate

Start the discussion